Three States Refuse Medicaid Coverage for Weight-Loss Drugs: What It Means for Colorado Patients
By Dr. Ethan Lazarus, MD
Board-Certified in Obesity Medicine and Family Medicine
Clinical Nutrition Center, Greenwood Village, CO
Three state Medicaid programs have carved weight-loss medications out of coverage — and Colorado is on the list by default, not by design.
Massachusetts MassHealth ends GLP-1 coverage for obesity on July 3, 2026, affecting roughly 22,000 residents. California’s Medi-Cal removed Wegovy, Zepbound, and Saxenda effective January 1, 2026. Both are “carve-outs.” That means states are actively removing obesity medications from the formulary. They are not just trimming them.
Colorado has not carved anything out. We never added it in. Health First Colorado does not cover Wegovy, Zepbound, Saxenda, Qsymia, Contrave, or Xenical for weight loss. These are excluded under Appendix P of the Preferred Drug List. GLP-1s are covered only for Type 2 diabetes. They are not covered for the disease of obesity itself.
When the headlines say “states are pulling back,” the honest version for Colorado is this: we never had it to pull. Roughly 150,000 Medicaid clients here would be eligible under proposed legislation. None are getting it today.
The Coverage Gap Is Real
Here is what I see in Greenwood Village:
A person with a BMI of 38 cannot afford $1,300 a month out of pocket for Zepbound.
A person with prediabetes and Class II obesity is told Medicaid covers the diabetes medication, but not the obesity medication.
A person who lost 60 pounds on Wegovy hits a coverage cliff and regains half of it within a year.
The pattern is consistent. Insurance routinely covers the consequences of obesity. Diabetes care, joint replacement, cardiac stents, sleep studies — all covered. But the upstream treatment? Routinely denied.
What Colorado Patients Can Actually Do
Three paths exist for people with obesity in the Denver metro:
- Self-pay. Manufacturer savings programs can lower the monthly cost ($149 – $449 / month). Eli Lilly’s Zepbound Lilly Direct Cash Program ($299 to start, $399 for 5 mg, $449 / month for higher doses) and Novo Nordisk’s Wegovy Cash Program ($199 to start, $349 for higher doses, $399 / month for HD) are examples. Note that Oral Wegovy and Foundayo are less expensive – $149 to start, $299 / month for higher doses.
- Medicare GLP-1 Bridge, starting July 1, 2026. CMS will offer eligible Part D beneficiaries access to certain GLP-1s for $50 per month through December 31, 2027. It is a time-limited demonstration, not a permanent benefit — but for eligible Coloradans, it is real money.
- An obesity medicine specialist who can navigate prior authorizations, alternative medications, and combination therapy. This is what we do at Clinical Nutrition Center.
The Bottom Line
The carve-outs in Massachusetts and California are a preview of the policy fight playing out in every state capitol. Colorado’s choice right now is silence. Appendix P simply excludes these drugs. Until the legislature acts, Medicaid patients in Denver, Aurora, Lakewood, and Centennial face the worst of both worlds: high obesity rates and no coverage for the most effective treatment we have.
If you are a person with obesity in Colorado and coverage is the only thing standing between you and treatment, call us. We will walk through the options that actually exist in 2026.
